Study backs genetic markers for early delivery risk :
This article was originally published in Clinica
Executive Summary
Pregnant women carrying specific interleukin-1 (IL-1) gene variations could be three times more likely to deliver pre-term babies than those without the variations, according to a US team. The IL-1 genetic factors produced a significant risk for pre-term delivery, independent of other risk factors such as smoking and age, said Amy Murtha of Duke University in Durham, North Carolina, who presented the findings at the Society for Maternal-Fetal Medicine in Miami earlier this month. San Antonio, Texas-based Interleukin Genetics which develops tests based on genetic factors that regulate control points in the inflammatory processes, said the gene variations in the study have previously been linked with an exaggerated inflammatory response.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.